Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?